Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

About this update from Madrigal Pharmaceuticals, Inc.

CONSHOHOCKEN, Pa. , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences: UBS Global Healthcare Conference 2024 Wednesday, November 13, 2024 at 2:00 P.M. EST The presentation will be webcast live and may be accessed here . 7th Annual Evercore HealthCONx Conference Wednesday, December 4, 2024 at 9:35 A.M. EST Piper Sandler 36th Annual Healthcare Conference Thursday, December 5, 2024 at 8:30 A.M. EST The fireside chats will be webcast live and can be accessed by visiting Madrigal’s Investor Relations Events page . About Madrigal Pharmaceuticals Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com . Investor Contact Tina Ventura , [email protected] Media Contact Christopher Frates, [email protected] Source: Madrigal Pharmaceuticals, Inc.

View stock analysis, news, and events for Madrigal Pharmaceuticals, Inc.